Exchange: NASDAQ·Updated 07:30 PM EST

NRIX News

News
all
press releases
NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nurix Therapeutics, Inc. (Nurix or the Company) (NASDAQ: NRIX) for violations of the securities laws.INVESTIGATION DETAILS: The investigation...
Business Wire
NRIX Investors Have Opportunity to Join Nurix Therapeutics, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nurix Therapeutics, Inc. (Nurix or the Company) (NASDAQ: NRIX) for violations of the securities laws.INVESTIGATION DETAILS: The investigation...
Business Wire
More News
Nurix Therapeutics (NASDAQ:NRIX) Sets New 52-Week Low - Time to Sell...
MarketBeat
Nurix Therapeutics, Inc. (NRIX) Presents at UBS Global Biopharma Conference 2026 Transcript...
SeekingAlpha
Roche wins FDA approval for Wilserdly plus everolimus, offering an all-oral treatment option for advanced breast cancer and strengthening its oncology portfolio.
Zacks
Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) have earned an average rating of "Moderate Buy" from the fifteen analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and fourteen have issued a buy re...
MarketBeat
Paris-headquartered Sanofi notified Nurix on Tuesday that it is ending the early-stage first-in-human trial of SAR448272 and terminating the program entirely.
Stocktwits
Sanofi notified Nurix that it is ending the early-stage first-in-human trial of SAR448272 and terminating the program entirely.
Stocktwits
Roche's sales rise 6% at constant exchange rates in the first nine months of 2026, as key drug growth offsets legacy product declines and pipeline advances.
Zacks
Kymera Therapeutics advances its targeted protein degradation pipeline, with KT-621 trials in atopic dermatitis and asthma marking key milestones amid competition in the field.
Zacks
(RTTNews) - Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period, primarily reflecting a major licensing revenue from its collaboration with Swiss drug major Roche Holding AG...
Nasdaq News: Markets

Advertisement|Remove ads.